Difference between revisions of "Tebentafusp (Kimmtrak)"
Jump to navigation
Jump to search
m |
m |
||
Line 7: | Line 7: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
*1/25/2022: Approved for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic [[uveal melanoma]]. ''(Based on IMCgp100-202)'' | *1/25/2022: Approved for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic [[uveal melanoma]]. ''(Based on IMCgp100-202)'' | ||
− | + | ==History of changes in EMA indication== | |
+ | *4/1/2022: Initial authorization as monotherapy for the treatment of human leukocyte antigen (HLA)-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma. | ||
==Also known as== | ==Also known as== | ||
*'''Code name:''' IMCgp100 | *'''Code name:''' IMCgp100 | ||
Line 18: | Line 19: | ||
[[Category:Immunotherapeutic]] | [[Category:Immunotherapeutic]] | ||
+ | [[Category:EMA approved in 2022]] | ||
[[Category:FDA approved in 2022]] | [[Category:FDA approved in 2022]] |
Revision as of 14:07, 3 January 2023
Mechanism of action
Bispecific protein consisting of an affinity-enhanced T-cell receptor fused to an anti-CD3 effector that can redirect T cells to target glycoprotein 100-positive cells.
Diseases for which it is used
History of changes in FDA indication
- 1/25/2022: Approved for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma. (Based on IMCgp100-202)
History of changes in EMA indication
- 4/1/2022: Initial authorization as monotherapy for the treatment of human leukocyte antigen (HLA)-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma.
Also known as
- Code name: IMCgp100
- Generic name: tebentafusp-tebn
- Brand name: Kimmtrak